Introduction
Mineralocorticoid receptor antagonists (MRAs; spironolactone and eplerenone) reduce mortality and morbidity in patients with New York Heart Association (NYHA) class II-IV heart failure with reduced ejection fraction (HFrEF) 1,2 and received class IA recommendation in guidelines. 3, 4 However, MRAs are underused in the USA 5 and Europe. 6, 7 Hyperkalaemia and worsening renal function have been addressed as potential explanations for this phenomenon, 8 although importantly their occurrence does not reduce the benefit of MRAs. 9, 10 Furthermore, the independent underlying reasons for MRA underuse in the real world are unknown.
The aim was to measure MRA non-use/use in a large unselected cohort of HFrEF patients, and to investigate the independent associations with MRA non-use.
Methods

Study protocol and setting
The Swedish Heart Failure Registry (SwedeHF; www.SwedeHF.se) has been previously described. 11 The only inclusion criterion is clinician-judged heart failure (HF). Approximately 80 variables are recorded at discharge from hospital or after an outpatient clinic visit on a web-based case report form and entered into a database managed by the Uppsala Clinical Research Center, Uppsala, Sweden (www .UCR.UU.se). The protocol, case report form and annual reports are available at www.SwedeHF.se.
The Swedish Board of Health and Welfare (www.socialstyrelsen.se) administers the Patient Registry that provided additional baseline co-morbidities, defined according to ICD-10 codes. ICD-10 coding in Sweden has been validated, with a positive predictive value ranging between 85% and 95% for most diagnoses. 12 Statistics Sweden (www.scb.se) provided socioeconomic characteristics. Recording of ICD codes and socioeconomic data occurs with a lag time and the procedures around linking to SwedeHF take time. Therefore, this study included SwedeHF registrations between 11 May 2000 (start of SwedeHF) and 31 December 2012, ensuring that all linked ICD code and socioeconomic data up to this date were available.
All Swedish citizens have unique personal identification numbers that allow linking of disease-specific health registries and governmental health and statistical registries.
Establishment of the HF registry and this analysis with linking of the above registries were approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out.
In SwedeHF, ejection fraction (EF) is categorized as <30%, 30-39%, 40-49%, and ≥ 50%. We included <30% and 30-39%. MRAs are indicated with symptoms, so NYHA class II-IV patients were included. MRAs were proven effective in NYHA class III-IV HFrEF in RALES in 1999 2 and in NYHA class II HFrEF in EMPHASIS-HF in 2011. 1 Thus, a consistency analysis including NYHA class III-IV from 2000 (start of the registry) and NYHA class II-IV from 2012 (when EMPHASIS-HF had been published and had time to penetrate the HF community) was performed. Patients with creatinine clearance <30 mL/min or K > 5.0 mEq/L were excluded from trials and do not have MRA indication. In the real world, many patients fluctuate around these cut-offs. If patients are already treated (which many may have been prior to the index date in this study), then worsening renal function or . 3 Therefore, the main analysis included the few patients with creatinine clearance <30 mL/min or K > 5.0 mEq/L, but a consistency analysis was also performed excluding these patients. MRAs are third-line therapy in HFrEF, so patients with HF duration ≥6 months were included to ensure adequate time for initiation of MRA therapy. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB) use was considered as a yes/no variable, but in order to evaluate the possibility that sub-target dosing of ACE-I/ARB may be a reason for MRA non-use, an additional consistency analysis was performed where ACE-I/ARB use was classified as target dose of ACE-I or ARB or use of both ACE-I and ARB vs. non-use or non-target dose of ACE-I or ARB. Registrations with missing data for MRA use, EF, NYHA class and HF duration were excluded.
Statistical analysis Baseline characteristics
Baseline characteristics of patients receiving vs. not receiving MRA were compared by t-test or Wilcoxon-Mann-Whitney to test continuous variables, and by chi-squared to test categorical variables. In a registry setting, patients may have missing baseline data. Excluding these patients from multivariable analyses would introduce bias due to the fact that baseline data are not completely missing at random. Therefore, missing data were managed by multiple imputation using chained equations method (n = 10). All analyses, except for descriptive statistics, were performed on imputed data.
Predictors of mineralocorticoid receptor antagonist non-use
In order to identify the independent predictors of MRA non-use, multivariable logistic regression models were performed using MRA non-use as dependent variable. Because predictors of MRA non-use are presently unknown and since the sample size was sufficiently large, we did not perform any stepwise variable selection procedure for choosing the variables to include in multivariable models. Instead, we included all variables from SwedeHF, the Patient Registry, and Statistics Sweden, which were clinically relevant and deemed potentially relevant in directly or indirectly affecting the decision to use MRAs. These added up to 39, marked with an asterisk in 
Results
Between 11 May 2000 (start of SwedeHF) and 31 December 2012, 80 772 registrations were recorded from 51 060 unique patients. Of these, 11 215 were patients with HFrEF, NYHA class II-IV and HF duration ≥6 months who reported no missing data for MRA use; 4443 (40%) patients were receiving MRA and 6772 (60%) were not ( Figure 1 ).
Baseline characteristics
In the overall population, the mean age was 75 ± 11 years, 27% were woman. There were numerous differences between untreated vs. treated patients, including higher age, more care in and follow-up referral to internal medicine, geriatrics, or primary care vs. cardiology. Notably, potassium and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were similar in those using and not using MRA. Untreated patients also received less ACE-I or ARB, digoxin, diuretics, oral anticoagulants, beta-blockers and HF devices, and if treated with ACE-I and/or ARB, also lower doses ( Table 1) .
Independent associations with mineralocorticoid receptor antagonist non-use
The differences in Figure 2 , and included e.g. lower creatinine clearance (<30 mL/min but also 30-59.9 mL/min was associated with non-use), no use of diuretics, no cardiac resynchronization therapy (CRT)/implantable cardioverter-defibrillator (ICD), higher blood pressure, higher EF, outpatient setting, older age, lower income, ischaemic heart disease, male sex, lower NYHA class, follow-up in primary care vs. cardiology/internal medicine, absence of hypertension diagnosis and later year of registration. Plasma potassium and NT-proBNP were not associated with MRA non-use. Non-use of digoxin remained associated with MRA non-use, whereas non-use of beta-blockers only approximated a statistically significance, and no association was reported between ACE-I/ARB use and other treatment use (nitrates, platelet inhibitors and statins) and MRA non-use. However, when doses of ACE-I/ARB were considered and ACE-I/ARB use was categorized as at (or above) target dose or use of both ACE-I and ARB vs. no use or sub-target dose (target doses for ACE-I and ARB are reported in the supplementary material online, Table S1 ), sub-target doses or no use was significantly associated with MRA non-use (OR 1.61; 95% CI 1.48-1.75) (Figure 2 ).
Other clinical variables/co-morbidities not associated with MRA non-use were body mass index, smoking, history of stroke/transient ischaemic attack, diabetes, lung disease, valvular disease, heart rate, atrial fibrillation, peripheral artery disease, previous coronary revascularization, and anaemia. Demographic/organizational variables not associated with MRA non-use were number of children, education level, living alone vs. being married/cohabitating, being registered in cardiology vs. internal medicine/geriatrics departments, and having a planned follow-up in a HF nurse-led clinic.
Consistency analysis
In the consistency analysis including patients in NYHA class II enrolled from 2012 only plus all the patients in NYHA class III-IV, 2939 (41%) received MRAs and 4177 (59%) did not. All the findings observed in the main analysis were confirmed except for NYHA class and hypertension that were not significantly associated with MRA non-use. We also repeated the analyses excluding patients with creatinine clearance <30 mL/min or missing and K > 5.0 mEq/L or missing. In this cohort, 2123 patients (40%) received MRAs and 3141 (60%) did not. rate ≥ 70 vs. <70 b.p.m., being registered in cardiology vs. internal medicine/geriatrics departments and higher number of children, whereas ischaemic heart disease, gender, age and year of registration were not associated with MRA non-use (supplementary material online, Figure S1 ).
Discussion
In the large and unselected nationwide SwedeHF, we observed that only 40% of patients with HFrEF, NYHA class ≥II and HF duration ≥6 months received MRA and that low creatinine clearance was a dominant risk factor for MRA non-use, even in the creatinine clearance 30-59.9 mL/min range where MRAs are not contraindicated. Furthermore, MRA use did not decrease with elevated potassium levels. MRA underuse might be further linked to non-specialist care, no use or sub-optimal dosing of ACE-I/ARB, milder HF, and perceived rather than actual risk of hyperkalaemia.
Underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients
The MRA underuse observed in the present study confirms previous analyses ( Table 2) . 5,7,13 -16 In the US Get With The Guidelines-HF quality improvement registry, only 32% of eligible patients received MRAs between 2005 and 2007, but a trend towards an increase in prescription over time was observed. 5 Similarly, an analysis from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) reported 36% of the eligible population treated by MRA. 13 In Europe, the EuroHeart Failure Survey II showed that 47.5% of patients discharged after a hospital admission for new-onset or decompensated HF received MRAs, 14 whereas in the European Society of Cardiology (ESC) HF pilot survey the rates were ∼50% in inpatients at discharge and 44% in outpatients. More recently, in the BIOSTAT-CHF programme enrolling patients with new-onset or worsening of HF who had not been previously treated with evidence-based therapies, 56% and 63% of eligible patients received MRA before and after HF treatment optimization, respectively, 7 whereas in the ESC HF Long-Term Registry ∼50% in inpatients at discharge and 44% in outpatients. BIOSTAT-CHF 7 56% of eligible patients before and 63% after HF treatment optimization. ESC-HF-LT 16 53.9% of patients hospitalized for acute HF received MRA at discharge and 56.5% at 1 year from hospitalization. SwedeHF (current study) 40% of the eligible population.
HF, heart failure; MRA, mineralocorticoid receptor antagonist.
(ESC-HF-LT) 53.9% of patients hospitalized for acute HF received MRA at discharge and 56.5% at 1 year from hospitalization.
16,17
Even when not considering MRAs indicated in NYHA class II until 2012, only 41% received MRAs in the present study. Similarly, when patients with K > 5.0 mEq/L and creatinine clearance <30 mL/min were excluded, again only 40% received MRAs. A previous analysis of SwedeHF has shown high utilization of renin-angiotensin system antagonists and beta-blockers that were prescribed in more than 90% of the population, but modest use of MRA that even decreased over time, from 53% in 2003 to 42% in 2012. 6 However, a major limitation of previous analyses is absence of explanatory factors. Therefore, a common assumption has simply addressed kidney disease and hyperkalaemia as major reasons for non-use. 
Patients characteristics independently associated with mineralocorticoid receptor antagonist non-use
Notably, in the present study, plasma potassium levels at baseline were not associated with MRA use decisions at baseline. The cause and effect relationship is of course difficult to establish, but hypokalaemia is likely a reason for use, and hyperkalaemia both a reason for non-use and a consequence of use. However, chronic kidney disease was a strong predictor of MRA non-use, with both creatinine clearance <30 and 30-59.9 mL/min associated with underuse. Creatinine clearance <30 mL/min associated with MRA non-use is expected since MRAs are contraindicated in severe renal disease. However, MRAs are not contraindicated and have been shown to be effective in reducing the risk of all-cause death, cardiovascular death and HF hospitalization in patients with estimated glomerular filtration rate 30-59.9 mL/min/1.73 m 2 ,
18
thus MRA underuse reported by our analysis in this subgroup is not justified. Similarly, we reported underuse in patients aged >75 years but MRAs have previously been shown to be equally effective also in the elderly. 18 These findings may suggest that a perceived risk of worsening renal function may have a role in MRA non-use. Relatedly, diuretic use was the strongest independent predictor of MRA use. One potential explanation for this observation could be that MRAs and loop diuretics were used to balance potassium levels and also in more severe HF. Hypertension was associated with use, whereas high blood pressure was associated with non-use, . . 19, 20 Indeed, a willingness and ability to undergo follow-up and monitoring is a requirement for MRAs (and other HF therapy) and although we cannot assess this willingness per se, many of the variables assessed may be indirect markers of low willingness or ability to undergo follow-up.
Limitations
Because of the cross-sectional nature of this study, for many associations described, cause and effect relationships cannot be established. We cannot rule out potential effects of unmeasured confounders affecting MRA non-use. We included patients enrolled in the SwedeHF between 2000 and 2012, thus, we cannot exclude any potential improvement in MRA prescriptions following the EMPHASIS-HF trial publication in 2011 1 and the consequent implementation of guidelines. We did not have access to type of MRA, but overall in Sweden, >98% of MRAs prescribed and dispensed are spironolactone. 21 Generalizability of our findings to other countries depends on similarities in population characteristics, health care and HF management. Finally, longitudinal data and time relationship between clinical variables, particularly previous measures of serum potassium levels that might have influenced decisions on whether or not to start an MRA, and medication use represent a major limitation of this and other registry studies.
Conclusions
There are still signals of MRA underuse in HFrEF. Reduced renal function, even in the 30-59.9 mL/min range, was associated with MRA underuse, but elevated potassium levels were not. Thus, we emphasize that the ESC HF guidelines recommend that while estimated glomerular filtration rate < 30 mL/min/1.73 m 2 or K > 5.0 mEq/L are contraindications to MRA initiation, for patients already treated with MRAs, renal function and K need to be considerably worse in order to consider dose reduction or discontinuation of MRAs. 3 
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